articleTop 1% cited
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
Leukemia · 2011 · Vol. 25(7) · pp. 1147–1152
Raphaël Itzykson✉(Université Sorbonne Paris Nord)Olivier Kosmider(Centre National de la Recherche Scientifique)Thomas Cluzeau(Hôpital l'Archet)Véronique Mansat‐De Mas(Hôpital Purpan)François Dreyfus(Assistance Publique – Hôpitaux de Paris)Odile Beyne‐Rauzy(Hôpital Purpan)Bruno Quesnel(Hôpital Claude Huriez)Norbert Vey(Institut Paoli-Calmettes)Véronique Gelsi‐Boyer(Institut Paoli-Calmettes)Sophie Raynaud(Hôpital l'Archet)Claude PreudhommeLionel Adès(Hôpital Avicenne)Pierre Fenaux(Hôpital Avicenne)Michaëla Fontenay(Université Paris Cité)on behalf of the Groupe Francophone des Myelodysplasies (GFM)
Acute Myeloid Leukemia ResearchEpigenetics and DNA MethylationChronic Myeloid Leukemia TreatmentsMyelodysplastic syndromesAzacitidineInternal medicineMyeloid leukemiaMedicineMyeloidLeukemiaOncologyGastroenterologyImmunology
Funding
- Celgene
Citations
464
FWCI
23.50
field-weighted impact
References
29
Percentile
100%
vs. same field & year
Citations per year
References
International Scoring System for Evaluating Prognosis in Myelodysplastic Syndromes
Blood · 1997 · 4,444 citations
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
The Lancet Oncology · 2009 · 2,624 citations
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Blood · 2006 · 1,576 citations
Proposals for the classification of the myelodysplastic syndromes
British Journal of Haematology · 1982 · 3,662 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.